Celyad Oncology SA is a clinical-stage biopharmaceutical company focused on discovering chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Their product candidates include CYAD-101, CYAD-211, and CYAD-02, which are in different phases of clinical trials to treat various cancer types, and CYAD-203, a non-gene edited allogeneic CAR-T candidate used to treat solid tumors. They have licensing agreements with Novartis International AG and research and development collaborations with Horizon Discovery Group.